Blog | HemaCare

HemaCare Leukopaks Used for Production of Allogeneic CAR T cells

May 28, 2019 10:04:00 AM / by Nancy Andon, MSc posted in Leukopak, CAR-T, allogeneic

0 Comments

A study out of Research Triangle Park, North Carolina [1] cites using HemaCare leukopaks as the starting material for new research on allogeneic CAR T cells.  

As most people know, the cancer fighting technique known as CAR T cell therapy has been getting a lot of attention these days, due to some remarkably positive clinical trial results. Two different versions of CAR T therapy have now earned FDA approval, so it seems that this type of therapy will inevitably be expanded to meet the needs of a considerably wider patient population. There’s a fairly large obstacle standing in the way of this expectation, however. Most clinical trials to date have been based on CAR T cell treatment as an autologous therapy, with the starting materials coming straight from the patients themselves. The problem with this autologous model is that it’s difficult to implement on a commercial scale, due to the limited availability of starting material.

Read More

Subscribe Here!

Posts by Topic

see all

Recent Posts